<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021159</url>
  </required_header>
  <id_info>
    <org_study_id>141052</org_study_id>
    <nct_id>NCT05021159</nct_id>
  </id_info>
  <brief_title>Assessing the Ontogeny of P-glycoprotein Expression in Blood of Pediatric Leukemic Patients</brief_title>
  <official_title>Assessing the Ontogeny of P-glycoprotein Expression in Blood of Pediatric Leukemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine P-glycoprotein expression in blood samples of Acute Lymphocytic leukemia (ALL)&#xD;
      pediatric patients receiving MTX treatment and trace its ontogeny and compare it with its&#xD;
      expression in pediatric healthy subjects. In addition, to determine the correlation of&#xD;
      P-glycoprotein expression and Methotrexate concentration at steady state.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 20 leukemic patients will be classified into three age groups according to the ages that&#xD;
      will be available at the time of sample collection.&#xD;
&#xD;
        -  All patients will be recruited from Tanta Oncology Center, Tanta University.&#xD;
&#xD;
        -  The study will be approved by the Research Ethics Committee of Tanta University and&#xD;
           college of Pharmacy ethical committee.&#xD;
&#xD;
        -  An informed consent will be obtained from parents of all patients in this research&#xD;
           before enrollment.&#xD;
&#xD;
        -  All patients' data will be private and confidential. Any unexpected risks that may&#xD;
           appear during the course of the research will be reported to patients and the ethical&#xD;
           committee on time.&#xD;
&#xD;
      Blood Samples will be obtained from healthy pediatric subjects of the same ages of the&#xD;
      diseased group subjects (Samples will be obtained from subjects from a primary care center&#xD;
      during their routine blood analysis excluding patients of chronic diseases, patients&#xD;
      receiving any medications, and patients of impaired kidney or liver functions).&#xD;
&#xD;
      P-glycoprotein expression will be estimated in all samples using Permeability glycoprotein&#xD;
      (P-gp), ELISA Kit, and its expression will be traced with development from the youngest till&#xD;
      the oldest age available, this will also be compared with normal healthy pediatric subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>P-gp expression in blood samples</measure>
    <time_frame>42 hours</time_frame>
    <description>P-gp expression in blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Methotrexate concentration in blood samples</measure>
    <time_frame>42 hours</time_frame>
    <description>Methotrexate concentration in blood samples</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Acute Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Methotrexate Group</arm_group_label>
    <description>20 acute lymphocytic leukemia patients receiving MTX treatment (3- 5 mg/ cm2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control group</arm_group_label>
    <description>20 healthy pediatric subjects not receiving any treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)</intervention_name>
    <description>the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression</description>
    <arm_group_label>Methotrexate Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric Acute Lymphocytic Leukemia Patients aged &lt; 18 years old who are already taking&#xD;
        the ALL MTX protocol.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric Acute Lymphocytic Leukemia Patients&#xD;
&#xD;
          -  aged &lt; 18 years old&#xD;
&#xD;
          -  who are already taking the ALL MTX protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe renal impairment (eGFR&lt; 30 mL/min/1.73 m2 at screening)&#xD;
&#xD;
               -  Critically ill patients.&#xD;
&#xD;
               -  Other types of cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasmine M Elmorsi, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant lecturer in Clinical Pharmacy Dept., Faculty of pahrmacy, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Osama M Ibrahim, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Professor in Clinical Pharmacy Dept., Faculty of pahrmacy, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tarek M Mostafa, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Assistant Professor in Clinical Pharmacy Dept., Faculty of pahrmacy, Tanta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Pharmacy, Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Gharbiya</state>
        <zip>31111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanta Cancer Center</name>
      <address>
        <city>Tanta</city>
        <state>Gharbiya</state>
        <zip>31111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Gharbiya</state>
        <zip>31111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009 Mar 27;323(5922):1718-22. doi: 10.1126/science.1168750.</citation>
    <PMID>19325113</PMID>
  </reference>
  <reference>
    <citation>Namanja HA, Emmert D, Davis DA, Campos C, Miller DS, Hrycyna CA, Chmielewski J. Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J Am Chem Soc. 2012 Feb 15;134(6):2976-80. doi: 10.1021/ja206867t. Epub 2011 Sep 9.</citation>
    <PMID>21866921</PMID>
  </reference>
  <results_reference>
    <citation>Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18;349(12):1157-67. Review.</citation>
    <PMID>13679531</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Yasmine Elmorsi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

